Baxter International Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Baxter International is gedaald met een gemiddeld jaarlijks percentage van -47.6%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 13.3%. De inkomsten zijn groeide met een gemiddeld percentage van 7.3% per jaar.
Belangrijke informatie
-47.6%
Groei van de winst
-47.3%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 7.3% |
| Rendement op eigen vermogen | -1.9% |
| Nettomarge | -1.0% |
| Volgende winstupdate | 08 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?
Sep 05
Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 05Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price
Apr 24Opbrengsten en kosten
Hoe Baxter International geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 14,997 | -157 | 3,542 | 668 |
| 31 Mar 24 | 14,892 | -38 | 3,512 | 658 |
| 31 Dec 23 | 14,813 | -76 | 3,495 | 655 |
| 30 Sep 23 | 15,280 | 225 | 3,484 | 642 |
| 30 Jun 23 | 14,574 | -3,050 | 3,467 | 625 |
| 31 Mar 23 | 14,461 | -2,673 | 3,489 | 608 |
| 31 Dec 22 | 14,506 | -2,666 | 3,550 | 599 |
| 30 Sep 22 | 14,275 | -2,568 | 3,435 | 580 |
| 30 Jun 22 | 13,892 | 876 | 3,212 | 562 |
| 31 Mar 22 | 13,396 | 992 | 2,957 | 553 |
| 31 Dec 21 | 12,146 | 1,022 | 2,605 | 530 |
| 30 Sep 21 | 12,451 | 1,214 | 2,530 | 528 |
| 30 Jun 21 | 12,197 | 1,120 | 2,460 | 521 |
| 31 Mar 21 | 11,817 | 1,068 | 2,370 | 499 |
| 31 Dec 20 | 11,673 | 1,102 | 2,405 | 519 |
| 30 Sep 20 | 11,531 | 911 | 2,360 | 516 |
| 30 Jun 20 | 11,410 | 924 | 2,383 | 528 |
| 31 Mar 20 | 11,526 | 991 | 2,414 | 552 |
| 31 Dec 19 | 11,362 | 1,001 | 2,442 | 561 |
| 30 Sep 19 | 11,156 | 1,335 | 2,348 | 554 |
| 30 Jun 19 | 11,066 | 1,484 | 2,359 | 573 |
| 31 Mar 19 | 11,060 | 1,505 | 2,399 | 595 |
| 31 Dec 18 | 11,099 | 1,552 | 2,401 | 618 |
| 30 Sep 18 | 11,063 | 1,065 | 2,527 | 636 |
| 30 Jun 18 | 11,009 | 795 | 2,572 | 632 |
| 31 Mar 18 | 10,763 | 840 | 2,478 | 621 |
| 31 Dec 17 | 10,584 | 609 | 2,516 | 615 |
| 30 Sep 17 | 10,432 | 1,025 | 2,424 | 584 |
| 30 Jun 17 | 10,283 | 904 | 2,382 | 564 |
| 31 Mar 17 | 10,263 | 1,852 | 2,447 | 560 |
| 31 Dec 16 | 10,163 | 4,966 | 2,520 | 566 |
| 30 Sep 16 | 10,121 | 4,909 | 2,566 | 573 |
| 30 Jun 16 | 10,050 | 4,784 | 2,625 | 584 |
| 31 Mar 16 | 9,940 | 3,646 | 2,704 | 582 |
| 31 Dec 15 | 9,968 | 393 | 2,832 | 589 |
| 30 Sep 15 | 10,154 | 337 | 2,972 | 585 |
| 30 Jun 15 | 10,376 | 510 | 3,087 | 593 |
| 31 Mar 15 | 9,274 | 84 | 3,037 | 473 |
| 31 Dec 14 | 10,719 | 457 | 3,182 | 608 |
| 30 Sep 14 | 12,252 | 739 | 3,301 | 743 |
| 30 Jun 14 | 13,253 | 1,092 | 3,334 | 847 |
| 31 Mar 14 | 15,367 | 1,967 | 3,437 | 1,047 |
| 31 Dec 13 | 9,413 | 315 | 2,859 | 534 |
Kwaliteitswinsten: BAX is momenteel verliesgevend.
Groeiende winstmarge: BAX is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BAX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 47.6% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van BAX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: BAX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 12.2% ).
Rendement op eigen vermogen
Hoge ROE: BAX heeft een negatief Return on Equity ( -1.92% ), omdat het momenteel verliesgevend is.